Sharekhan

Syncom Formulation (India) Ltd

Wed 30/04/2025,15:57:22 | NSE : SYNCOMF

₹ 16.32-0.49 (-2.91%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 16.81

Previous Close

₹ 16.81

Volume

2213456

Mkt Cap ( Rs. Cr)

₹1534.08

High

₹ 16.89

Low

₹ 16.25

52 Week High

₹ 27.90

52 Week Low

₹ 10.95

Book Value Per Share

₹ 3.34

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Syncom Formulation (India) Ltd

Your Vote -

Buy

76.85%

Hold

17.28%

Sell

5.87%

76.85%

1823 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

16.32

109

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

109

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Syncom Formulation (India) Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Syncom Formul. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    17 Apr 2025, 12:55PM Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Syncom Formul. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    17 Apr 2025, 12:42PM Certificate for Compliance of Regulation 74(5) of SEBI, DP REG 2018 for the Quarter ended 31.03.2025
  • Syncom Formul. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    15 Apr 2025, 4:42PM As of March 2025, 50.57% is owned by Indian Promoters and 49.43% by Public. <p align=justify> Top five Promoters holding highest number of shares of S
  • Syncom Formul. - General Updates

    5 Apr 2025, 6:11PM Syncom Formulations (India) Limited has informed the Exchange about General Updates
  • Syncom Formul. - Announcement Under Regulation 30

    5 Apr 2025, 6:04PM Announcement under Regulation 30 for the demand raised under section 74 (5) of CGST ACT, 2017
  • Syncom Formul. - Trading Window-XBRL

    25 Mar 2025, 5:53PM SYNCOM FORMULATIONS (INDIA) LIMITED has informed the Exchange about Closure of Trading Window
  • Syncom Formul. - Trading Window

    25 Mar 2025, 5:52PM Syncom Formulations (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) R
  • Syncom Formul. - Updates

    5 Mar 2025, 3:09PM Syncom Formulations (India) Limited has informed the Exchange regarding 'Submission of Machine Readable / Legible Copy of Financial Results for the Pe
  • Syncom Formul. - Disclosure of material issue

    13 Feb 2025, 3:08PM Syncom Formulations (India) Limited has informed regarding Disclosure of material issue
  • Syncom Formul. - Disclosure under Regulation 30A of LODR

    13 Feb 2025, 2:57PM We are Pleased to Inform the Installation of Solar Rooftop Project for Captive Consumption
  • Syncom Formul. - Copy of Newspaper Publication

    11 Feb 2025, 4:41PM Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication
  • Syncom Formul. - Integrated Filing- Financial

    10 Feb 2025, 4:42PM Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024.
  • Syncom Formul. - Financial Result Updates

    10 Feb 2025, 4:34PM Syncom Formulations (India) Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Syncom Formul. Q3 net profit jumps 99.22% at Rs 12.79 cr

    10 Feb 2025, 4:40PM The company reported standalone net profit of Rs 12.79 crore for the quarter ended December 31, 2024 as compared to Rs 6.42 crore in the same period l
  • Syncom Formul. - Integrated Filing (Financial)

    10 Feb 2025, 4:40PM Pursuant to SEBI Circular No SEBI/HO/CFD/CFD-POD-2/CIR/P/2024/185 DATED 31.12.2024 We are submitting herewith the integrated Filing financials for the
  • Syncom Formul. - Regulation 33(3) Of SEBI (LODR) Regulations, 2015 - Submission Of Standalone & Consolidated Unaudited Financ

    10 Feb 2025, 4:32PM Consideration and approval of standalone and consolidated unaudited financial results for the quarter and nine months ended 31.12.2024
  • Syncom Formul. - Board Meeting Intimation

    3 Feb 2025, 3:21PM SYNCOM FORMULATIONS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 10-Feb-2025 to consider and approve the Quarterly Unau
  • Syncom Formul. - Compliances-Reg. 50 (1) - Prior intimation about Board meeting under Regulation 50(1)

    3 Feb 2025, 3:04PM Prior Intimation of Board Meeting

Key fundamentals

Evaluate the intrinsic value of Syncom Formulation (India) Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 358.1021 339.1962 280.0124 249.674 147.7977
Liabilities 358.1021 339.1962 280.0124 249.674 147.7977
Equity 94 94 86.2453 78.9952 78.0652
Gross Profit 27.8543 19.6132 19.4629 37.8388 16.64
Net Profit 23.6232 20.0707 19.7904 29.1719 14.2534
Cash From Operating Activities -5.9376 10.4962 16.329 -150.1536 -0.5056
NPM(%) 9.14 8.93 9 11.91 6.93
Revenue 258.3596 224.6439 219.6632 244.805 205.511
Expenses 230.5053 205.0307 200.2003 206.9661 188.871
ROE(%) 7.53 6.4 6.31 9.3 4.54

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Syncom Formulation (India) Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 825.75 -1.80 11.65 9.31 1321.50 1.39
Lotus Eye Hospital and Institute Ltd 81.22 -0.17 338.42 33.94 14.01 0.62
Vaishali Pharma Ltd 13.47 -1.82 449.00 17.49 2.76 0.00
Astec Lifesciences Ltd 685.90 -1.03 0.00 32.00 -687.11 0.00

Company Info

Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health. -Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500 products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly 1988 -Syncom Formulation (India) Ltd. was established. 2005 -Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis. 2006 -Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis. -The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra. 2008 -Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company. -On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company. -On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each. 2009 -Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each -Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2 2011 -Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company 2012 -Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates -Shri. Praveen Jindal has been appointed as an Independent Director of the company. 2013 -The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange. -The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13, -Syncom Formulation (India) has announces bonus in the ratio of 5:2 -Syncom Formulation (India) has splits its face value from Rs 10/- to 1/- 2014 -The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14 -The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014. 2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.

Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health. -Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500 products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly 1988 -Syncom Formulation (India) Ltd. was established. 2005 -Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis. 2006 -Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis. -The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra. 2008 -Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company. -On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company. -On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each. 2009 -Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each -Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2 2011 -Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company 2012 -Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates -Shri. Praveen Jindal has been appointed as an Independent Director of the company. 2013 -The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange. -The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13, -Syncom Formulation (India) has announces bonus in the ratio of 5:2 -Syncom Formulation (India) has splits its face value from Rs 10/- to 1/- 2014 -The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14 -The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014. 2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.

Read More

Parent Organisation

Syncom Formulation (India) Ltd.

Founded

21/06/1988

Managing Director

Mr.Vijay Shankarlal Bankda

NSE Symbol

SYNCOMFEQ

FAQ

The current price of Syncom Formulation (India) Ltd is ₹ 16.32.

The 52-week high for Syncom Formulation (India) Ltd is ₹ 16.89 and the 52-week low is ₹ 16.25.

The market capitalization of Syncom Formulation (India) Ltd is currently ₹ 1534.08. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Syncom Formulation (India) Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Syncom Formulation (India) Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Syncom Formulation (India) Ltd shares.

The CEO of Syncom Formulation (India) Ltd is Mr.Vijay Shankarlal Bankda, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT